Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.

@article{Inoue2015ClinicopathologicalAS,
  title={Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.},
  author={Yusuke Inoue and Shun Matsuura and Nobuya Kurabe and Tomoaki Kahyo and Hiroki Mori and Akikazu Kawase and Masato Karayama and Naoki Inui and Kazuhito Funai and Kazuya Shinmura and Takafumi Suda and Haruhiko Sugimura},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2015},
  volume={10 11},
  pages={1590-600}
}
INTRODUCTION Gene amplification is an important genetic change in cancer cells. We investigated the prevalence, clinicopathological characteristics, and prognostic value of NKX2-1 (also known as TTF-1), SETDB1, MET, HER2, SOX2, FGFR1, and PIK3CA amplification in Japanese patients with non-small-cell lung cancer (NSCLC). METHODS The copy numbers of the seven above-mentioned genes were assessed using fluorescence in situ hybridization in a tissue microarray containing 282 surgically resected… CONTINUE READING